Florida did not sue Pfizer over whether the COVID-19 shot "worked." It sued over what the company said while selling it.
On October 1, 2026, Attorney General James Uthmeier filed a 49-page complaint in St. Lucie County circuit court against Pfizer Inc. and, personally, chairman and CEO Albert Bourla. The case is brought only under the Florida Deceptive and Unfair Trade Practices Act. It asks for an injunction, disgorgement of profits, and civil penalties of $10,000 per violation, or $15,000 when the consumer was a senior or a person with a disability. No federal claim is pleaded. The complaint says so on purpose.
That drafting choice is the whole strategy. A similar Texas suit, filed by Ken Paxton, was thrown out on December 30, 2024, after removal to federal court, on the ground that the Public Readiness and Emergency Preparedness Act immunized Pfizer. The Fifth Circuit was still poking at jurisdiction in that case as of September 2026. Florida is trying to stay in state court, and to stay outside the PREP Act's "claim for loss," by framing this as a consumer-protection enforcement action by the Department of Legal Affairs rather than a damages suit over injury from a covered countermeasure. Whether that distinction survives removal is the first fight, and probably the decisive one.
The complaint opens with a deliberately provocative line from Bourla in November 2021. Referring not to vaccine-hesitant people generally, but to a small group he accused of deliberately spreading vaccine misinformation, Bourla said: "Those people are criminals."
The first is absolute safety. On April 1, 2021, Pfizer said there were "no serious safety concerns" through six months after a second dose. In a 2023 CNBC interview Bourla said the company had "not seen a single [safety] signal" after billions of doses. The state says that was false by omission. Federal officials in the United States and Israel had already identified a myocarditis and pericarditis signal in 2021, concentrated in adolescent and young-adult males, mostly in the week after vaccination. U.S. labels were updated that year. In 2023 the CDC described the link as causal. Pfizer's own site now says the data "demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination." The complaint also points to an early company safety database — 42,086 case reports, 158,893 adverse events, 1,223 reported deaths — and argues that possession of those reports sat badly next to blanket public assurances. The filing itself concedes Pfizer had not found those deaths causal. An adverse-event report is not proof of cause. An adverse-event report is not proof of cause, nor does every report constitute a safety signal. Florida's narrower argument is that the volume and character of the reports, combined with other emerging safety information, made Pfizer's sweeping public assurances misleading.
The pregnancy allegations are thinner. The state cites foetal abnormalities in a rat study and early reports of miscarriage, plus internal concern later attributed to Anthony Fauci, Vivek Murthy, and Rochelle Walensky. Pfizer told Australian regulators the rat findings were "not considered to be treatment-related." The current label says there are no available data on use before 24 weeks' gestation to inform the risk of major birth defects and miscarriage. "No available data" is not the same thing as "known to cause miscarriage." A court will have to decide whether the marketing crossed from incomplete into deceptive.
The second theme is transmission, and here the record is cleaner. In December 2020 Bourla said the choice not to vaccinate "will not affect only your health or your life" but "the lives of others and likely the lives of the people you love the most." The complaint says the company pressed a moral duty to vaccinate in order to stop spread. That month the FDA said there was no evidence the vaccine prevented transmission. The pivotal trials were not designed to measure it. In 2022 a Pfizer executive told the European Parliament the vaccine had not been tested on stopping transmission. Relative reduction in symptomatic disease is not the same claim as "you will not infect the people you love." Public officials blurred those claims too. The suit treats the blur as Pfizer's sales pitch.
The money is part of the pleading because FDUTPA cares about trade. The state says Pfizer spent more than $10 billion on advertising from 2020 to 2023, took in more than $80 billion from the vaccine, held roughly 70 percent of the U.S. and European COVID-vaccine market, and later raised the private-sector price from about $30 a dose to $110–$130. Bourla's compensation over those four years was about $102 million, excluding stock sales. CDC figures cited in the complaint put 6,745,860 Pfizer doses into Florida by September 6, 2026. Pfizer's Tampa "Global Capability Hub" is offered as a jurisdictional hook.
Pfizer's answer, given to Reuters and Politico, is short. The allegations have no merit. The representations were accurate and science-based. The company stands behind the safety and efficacy of the vaccine. That defence has a real core. Large observational studies found the original series sharply reduced hospitalisation and death in 2021, before Omicron and before immunity waned. Myocarditis after mRNA vaccination is a documented, labelled risk; it is also uncommon, usually mild, and has to be set against myocarditis from the infection itself. Reporting systems collect suspicions, not verdicts. A press release that survives FDA review is not automatically a consumer fraud.
What the case is really testing is the gap between the label and the microphone. Emergency authorisation was granted on prevention of disease, not on sterilising immunity, and not on a finished pregnancy dataset. Executives and officials then spoke as if both questions were closed. Florida's theory is that the gap was a sales tactic, aimed at a frightened public, enforced by calling sceptics criminals, and cashed out at $80 billion. Pfizer's theory is that evolving science, disclosed to regulators and later printed on the label, is not deceit.
Neither theory has been tried. The Texas case died, for now, on immunity rather than on the facts. If Florida's complaint stays in St. Lucie County, a state judge will have to decide whether "no serious safety concerns" and "not a single signal" were fair descriptions of a product whose own maker now warns of heart inflammation, and whether a moral argument about protecting others was a fair description of a trial that never measured transmission. Those are pleading questions today. They are the questions the marketing left behind.
https://www.theepochtimes.com/us/pfizer-deceived-public-over-covid-19-vaccine-safety-lawsuit-alleges-6098688